Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
01.02.2020 January 2020: A combination of trastuzumab with tailored dose-dense adjuvant chemotherapy reduces risk of relapse in HER2-positive breast cancer
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
20.01.2020 Save the date: ESMO Breast Cancer 2020
ESMO Breast Cancer 2020 will take place on 7-9 May 2020 in Berlin, Germany.
01.01.2020 December 2019: HLA class I evaluation in breast cancer patients from GeparTrio trial
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
12.12.2019 SABCS 2019: Effects of capecitabine in neo-/adjuvant chemotherapy
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
11.12.2019 MammaMia Patientenkongress 2020
MammaMia! Patientenkongress Gynäkologische Krebserkrankungen am 2. Februar in Frankfurt.
06.12.2019 GBG presentations at SABCS
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
21.10.2019 ESMO 2019 Congress: Merit Award
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
30.09.2019 Save the date: GBG-Jahrestreffen 2020
Das GBG-Jahrestreffen 2020 findet vom 27.-28. Februar in Frankfurt statt.
30.09.2019 Save the date: AGO State of the Art Meeting
Das AGO-Mamma State of the Art Meeting 2020 findet am 29. Februar in Frankfurt statt.
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
18.09.2019 TAXIS (GBG101) – 1ste Patientin in Deutschland
Am 17. September 2019 wurde die 1ste Patientin in die TAXIS-Studie eingeschlossen.
17.09.2019 GBG Forschung beim ESMO 2019
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
08.07.2019 Fortbildung Checkpoint-Inihibitoren
Fortbildungsveranstaltung „Behandlung mit Checkpoint-Inihibitoren“ der GBG und des BreastNet Rhein Main am 27. August 2019 von 17:00 – 20:00 Uhr in Frankfurt
04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) have been published in the Annals of Oncology.
03.06.2019 May 2019: Long-term outcomes of the GeparSepto study
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
27.05.2019 GBG Studien beim ASCO 2019: Ein Erfolg auf ganzer Linie
Auf dem ASCO-Kongress 2019 konnten wir einige Ergebnisse und neue Studienkonzepte der GBG vorestellen.
